Financial reports
10-Q
2024 Q1
Quarterly report
10 May 24
10-K
2023 FY
Annual report
22 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
28 Mar 22
Current reports
8-K
Departure of Directors or Certain Officers
14 May 24
8-K
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
10 May 24
8-K
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
22 Mar 24
8-K
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
18 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Feb 24
8-K
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
30 Jan 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
8-K
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
18 Dec 23
8-K
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
13 Nov 23
8-K
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
3 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
24 May 24
S-3
Shelf registration
29 Mar 24
D
Exempt offering of security
5 Feb 24
424B5
Prospectus supplement for primary offering
30 Jan 24
S-3
Shelf registration
17 Nov 23
S-8
Registration of securities for employees
17 Nov 23
424B5
Prospectus supplement for primary offering
31 Jul 23
424B5
Prospectus supplement for primary offering
24 May 23
D
Indefinite amount in options / securities to be acquired, 9 investors
14 Apr 23
S-3
Shelf registration
6 Apr 23
Proxies
DEFA14A
Additional proxy soliciting materials
2 Apr 24
DEF 14A
Definitive proxy
2 Apr 24
PRE 14A
Preliminary proxy
22 Mar 24
DEF 14A
Definitive proxy
1 May 23
PRE 14A
Preliminary proxy
21 Apr 23
DEF 14C
Information statement
14 Nov 22
PRE 14C
Preliminary information
4 Nov 22
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
Other
EFFECT
Notice of effectiveness
8 Apr 24
EFFECT
Notice of effectiveness
27 Nov 23
CORRESP
Correspondence with SEC
21 Nov 23
UPLOAD
Letter from SEC
21 Nov 23
EFFECT
Notice of effectiveness
8 May 23
EFFECT
Notice of effectiveness
8 May 23
EFFECT
Notice of effectiveness
8 May 23
CORRESP
Correspondence with SEC
3 May 23
CORRESP
Correspondence with SEC
3 May 23
CORRESP
Correspondence with SEC
3 May 23
Ownership
4
WILLIAM GARRETT GRAY
24 May 24
4
James F Oliviero III
24 May 24
3
Initial statement of insider ownership
24 May 24
SC 13D/A
Fortress Biotech, Inc.
17 May 24
4
MICHAEL S WEISS
16 May 24
4
Sharma Amit
16 May 24
4
BARRY M SALZMAN
16 May 24
4
LINDSAY A MD ROSENWALD
16 May 24
4
Neil Herskowitz
16 May 24
4
Christian Bechon
16 May 24